Hypertrophic cardiomyopathy {#sec1-1}
===========================

Hypertrophic cardiomyopathy (CMH) is characterized by an increase in the number of heart muscle cells. It is frequently caused by mutations in genes encoding sarcomeric proteins, leading to myocyte disarray, a hallmark of CMH ([@ref2]).

Clinical symptoms range from asymptomatic left ventricular hypertrophy to progressive heart failure or sudden cardiac death, and vary from individual to individual even within the same family. Frequent symptoms include dyspnea, chest pain, palpitations, orthostasis, presyncope and syncope. Usually CMH becomes apparent during adolescence or early adulthood, although it may also develop in different stages of life such as old age, infancy or childhood ([@ref3]).

Hypertrophic cardiomyopathy is a relatively common inherited heart disease with a prevalence of 1:500 in the population ([@ref4]). Clinical diagnosis is based on patient history, physical examination, echocardiography and ECG to detect hypertrophy ([@ref2]). The genetic test is useful for confirming diagnosis, and for differential diagnosis, recurrence risk evaluation and prenatal diagnosis in families with a known mutation. Differential diagnosis should consider acquired left ventricular hypertrophy, Danon disease, Fabry disease, cardiac amyloidosis, glycogen storage disease type II, Noonan syndrome and Friedreich ataxia ([@ref5]).

The European Society of Cardiology recommends genetic testing in the following cases ([@ref6]):

1.  patients meeting diagnostic criteria for CMH, when testing enables cascade genetic screening of their relatives;

2.  in first-degree adult relatives of patients with a definite disease-causing variant;

3.  in first-degree adult relatives, clinical screening with ECG and echocardiogram should be offered when genetic testing is not performed in the proband, or when genetic analysis fails to identify a definite mutation or reveals one or more genetic variants of unknown significance;

4.  children of patients with a definite disease-causing mutation should be considered for predictive genetic testing after pre-test family counseling when they are at least 10 years old;

5.  when there is a family history of childhood malignancies or early-onset disease or when children have heart symptoms or are involved in particularly demanding physical activity, clinical or genetic testing of first-degree child relatives may be considered before the age of 10 years.

Hypertrophic cardiomyopathy typically has autosomal dominant inheritance. Pathogenic variants may be missense, nonsense, splicing or small indels ([Table 1](#T1){ref-type="table"}). Large deletions/duplications have also been reported in the *NEXN*, *TNNI3*, *MYBPC3, CAV3* and *MYH7* genes.

###### 

Genes associated with various forms of hypertrophic cardiomyopathy

  Gene       OMIM gene   Disease                      OMIM disease   Inheritance   Function
  ---------- ----------- ---------------------------- -------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *MYH7*     160760      CMH1                         192600         AD            Beta heavy chain subunit of cardiac myosin
  *CAV3*     601253      CMH1                         192600         AD            Regulates voltage-gated K^+^ channels and plays a role in sarcolemma repair in cardiomyocytes after mechanical stress
  *MYLK2*    606566      CMH1                         192600         AD            Cardiac Ca^2+^/calmodulin-dependent myosin light chain
  *TNNT2*    191045      CMH2                         115195         AD            Ca^2+^-dependent regulator of muscle contraction
  *TPM1*     191010      CMH3                         115196         AD            Ca^2+^-dependent regulator of striated muscle contraction
  *MYBPC3*   600958      CMH4                         115197         AD            Cardiac isoform of myosin-binding protein C found in cross-bridge-bearing zone (C region) of A bands
  *PRKAG2*   602743      CMH6                         600858         AD            Energy-sensing enzyme that monitors cell energy status and functions. Inhibitor of de novo biosynthesis of fatty acids and cholesterol
  *TNNI3*    191044      CMH7                         613690         AD            Cardiac mediator of striated muscle relaxation
  *MYL3*     160790      CMH8                         608751         AD            Ventricular isoform of myosin light chain 3
  *TTN*      188840      CMH9                         613765         AD            Important for assembly and functioning of striated muscles, it connects microfilaments and contributes to balance of forces between two halves of sarcomere
  *MYL2*     160781      CMH10                        608758         AD            Regulatory light chain associated with cardiac myosin beta heavy chain, promoting cardiac myofibril assembly
  *ACTC1*    102540      CMH11                        612098         AD            ACTC1 is localized in contractile apparatus of muscle tissues
  *CSRP3*    600824      CMH12                        612124         AD            Positive regulator of myogenesis; transcription cofactor for myogenic bHLH transcription factors
  *TNNC1*    191040      CMH13                        613243         AD            TNNC1 encodes Tn-C that abolishes inhibitory action of Tn on actin filaments upon Ca^2+^ binding
  *MYH6*     160710      CMH14                        613251         AD            Alpha heavy chain subunit of cardiac myosin
  *VCL*      193065      CMH15                        613255         AD            VCL encodes an actin filament-binding protein that regulates cell-matrix adhesion, cell-cell adhesion, cell-surface E-cadherin expression, mechanosensing by E-cadherin complex, cell morphology and cell locomotion
  *MYOZ2*    605602      CMH16                        613838         AD            MYOZ2 encodes myozenin that binds proteins involved in linking Z line proteins and localizing calcineurin signaling to sarcomeres. May play a role in myofibrillogenesis
  *JPH2*     605267      CMH17                        613873         AD            JPH2 is necessary for intracellular Ca^2+^ signaling in cardiac myocytes via ryanodine receptor-mediated Ca^2+^ release
  *PLN*      172405      CMH18                        613874         AD            Modulates contractility of heart muscle in response to physiological stimuli via ATP2A2 regulates Ca^2+^ reuptake during muscle relaxation and Ca^2+^ homeostasis in heart muscle
  *CALR3*    611414      CMH19 (?)                    613875         AD            Ca^2+^-binding chaperone localized in endoplasmic reticulum
  *NEXN*     613121      CMH20                        613876         AD            Essential for maintenance of sarcomere integrity
  *MYPN*     608517      CMH22                        615248         AD            Component of cardiac muscle sarcomere that links nebulette to alpha-actinin in Z lines
  *ACTN2*    102573      CMH23 with or without LVNC   612158         AD            Localized in Z-disc of cardiac muscle where it anchors myofibrillar actin filaments
  *LDB3*     605906      CMH24                        601493         AD            Adaptor protein in striated muscle; couples protein kinase C-mediated signaling to cytoskeleton
  *TCAP*     604488      CMH25                        607487         AD            Muscle assembly regulating factor that mediates antiparallel assembly of titin molecules at sarcomere Z-disk
  *FLNC*     102565      CMH26                        617047         AD            Critical for myogenesis and structural integrity of muscle fibers

CMH=hypertrophic cardiomyopathy; LVNC=left ventricular non-compaction; AD=autosomal dominant; AR=autosomal recessive

The mutation detection rate for the most common mutant genes is \~56% (*MYBPC3* 20-30%; *MYH7* 20-30%; *TNNT2* 3-5%; *TNNI3* 3-5%; *TPM1* 1-3%) ([@ref7]). MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and MLPA to detect duplications and deletions in *NEXN*, *TNNI3*, *MYBPC3*, *CAV3* and *MYH7*. Worldwide, 151 accredited medical genetic laboratories in the EU and 19 in the US, listed in the Orphanet ([@ref8]) and GTR ([@ref9]) databases, respectively, offer genetic tests for hypertrophic cardiomyopathy. The clinical guidelines for genetic testing are described in Genetics Home Reference ([@ref10]), GeneReviews ([@ref5]) and Clinical Utility Gene Card ([@ref7]).

Dilated cardiomyopathy {#sec1-2}
======================

Dilated cardiomyopathy (CMD) is a heart disorder characterized by dilation of at least one ventricle and systolic dysfunction. The ventricle wall becomes thinner and its contractile force decreases. Clinical signs are usually arrhythmias, thromboembolic events, such as stroke, and above all symptoms of heart failure, such as edema, orthopnea, dyspnea and fatigue. However, the symptoms take years to cause health problems and severity varies between affected individuals.

The etiology of CMD may include either inherited or acquired causes, such as myocardial infarction, valve disease, toxins, drugs, inflammatory conditions, long-standing severe hypertension and irradiation of the chest ([@ref11]). Dilated cardiomyopathy is essentially an adult-onset disease, but has shown a highly variable age of onset ([@ref12]). The prevalence is 1:2700 ([@ref13]). It can be classified as acquired, syndromic or non syndromic.

Diagnosis is established when left ventricular enlargement and systolic dysfunction are both ascertained. Patient history, physical examination and echocardiography are also indispensable for the diagnostic process ([@ref12]). The genetic test is useful for diagnosis confirmation, differential diagnosis, recurrence risk evaluation and prenatal diagnosis in families with a known mutation. Differential diagnosis should consider acquired dilated cardiomyopathies, syndromic forms and other cardiomyopathies that may present with left ventricular involvement ([@ref14]). Syndromic forms include *HFE*-associated hereditary hemochromatosis, Emery-Dreifuss muscular dystrophy, Laing distal myopathy, Carvajal syndrome, Duchenne and Becker muscular dystrophy, Barth syndrome and mitochondrial dilated cardiomyopathies ([@ref15]).

Dilated cardiomyopathy is a genetically heterogeneous disease and has different modes of inheritance ([Table 2](#T2){ref-type="table"}). Pathogenic variants may be missense, nonsense, splicing and small indels. Large deletions/duplications have also been reported in *LMNA, MYH7, SCN5A, BAG3, DES, EYA4, SGCD, MYBPC3, NEXN, PRDM16, PSEN1, TNNI3, DND, RAF1, FKTN* and *TAZ*. The mutation detection rates for the most frequently mutant CMD-related genes are *TTN* 18-25%, *LMNA* 6%, *MYH7* 4-5%, *MYH6* 3-4%, *MYBPC3* 2-4%, *TNNT2* 3%, *BAG3* 2-3%. ([@ref16]).

###### 

Genes associated with various forms of dilated cardiomyopathies

  Gene       OMIM gene   Disease                                             OMIM disease     Inheritance   Function
  ---------- ----------- --------------------------------------------------- ---------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *LMNA*     150330      CMD1A                                               115200           AD            Required for cardiac homeostasis
  *MYH7*     160760      CMD1S                                               613426           AD            Beta heavy chain subunit of cardiac myosin
  *MYH6*     160710      CMD1EE                                              613252           AD            Alpha heavy chain subunit of cardiac myosin.
  *SCN5A*    600163      CMD1E                                               601154           AD            Mediates voltage-dependent Na^+^ permeability of excitable membranes
  *ACTN2*    102573      CMD1AA with/without LVNC                            612158           AD            Localized in the Z-disc of cardiac muscle where it anchors myofibrillar actin filaments
  *DSG2*     125671      CMD1BB                                              612877           AD            Ca^2+^-binding transmembrane glycoprotein component of desmosomes between myocardial cells
  *LDB3*     605906      CMD1C with/ without LVNC                            601493           AD            Adaptor protein in striated muscle; couples protein kinase C-mediated signaling to cytoskeleton
  *TNNT2*    191045      CMD1D                                               601494           AD            Ca^2+^-dependent regulator of muscle contraction
  *RBM20*    613171      CMD1DD                                              613172           AD            RNA-binding protein that regulates mRNA splicing of genes involved in heart development, such as TTN
  *TTN*      188840      CMD1G                                               604145           AD            Important for striated muscle assembly and function, connects microfilaments, contributes to balance of forces between two halves of sarcomere
  *BAG3*     603883      CMD1HH                                              613881           AD            Co-chaperone for HSP70 and HSC70 chaperone proteins in heart; triggers client/substrate protein release
  *DES*      125660      CMD1I                                               604765           AD            Sarcomeric microtubule-anchoring protein that maintains sarcomere structure
  *CRYAB*    123590      CMD1II                                              615184           AD            Has chaperone-like activity, preventing aggregation of proteins under stress conditions
  *EYA4*     603550      CMD1J                                               605362           AD            Transcriptional regulator during organogenesis
  *LAMA4*    600133      CMD1JJ                                              615235           AD            Mediates attachment, migration and organization of cells into tissues during embryo development by interacting with other extracellular matrix components
  *MYPN*     608517      CMD1KK                                              615248           AD            Component of heart muscle sarcomere linking nebulette to alpha-actinin in Z lines
  *SGCD*     601411      CMD1L                                               606685           AD            Component of sarcoglycan complex linking F-actin cytoskeleton and extracellular matrix
  *CSRP3*    600824      CMD1M                                               607482           AD            Positive regulator of myogenesis; transcription cofactor for myogenic bHLH transcription factors
  *ABCC9*    601439      CMD1O                                               608569           AD            Activates and regulates cardiac and smooth muscle- type KATP channels
  *PLN*      172405      CMD1P                                               609909           AD            Modulates contractility of heart muscle in response to physiological stimuli via ATP2A2; regulates Ca^2+^ re-uptake during muscle relaxation and Ca^2+^ homeostasis in heart muscle
  *ACTC1*    102540      CMD1R                                               613424           AD            Localized in contractile apparatus of muscle tissue
  *MYBPC3*   600958      CMD1MM                                              615396           AD            Cardiac isoform of myosin-binding protein C found in cross-bridge-bearing zone (C region) of A bands
  *PRDM16*   605557      CMD1LL                                              615373           AD            Transcriptional cofactor essential for heart development
  *PSEN1*    104311      CMD1U                                               613694           AD            Expressed in heart and critical for heart development
  *PSEN2*    600759      CMD1V                                               613697           AD            Expressed in heart and critical for heart development
  *TPM1*     191010      CMD1Y                                               611878           AD            Ca^2+^-dependent regulator of striated muscle contraction
  *VCL*      193065      CMD1W                                               611407           AD            Encodes an actin filament-binding protein that regulates cell-matrix adhesion, cell-cell adhesion, cell-surface E-cadherin expression, mechanosensing by the E-cadherin complex, cell morphology and cell locomotion
  *TNNC1*    191040      CMD1Z                                               611879           AD            Encodes Tn-C that abolishes inhibitory action of Tn on actin filaments upon Ca^2+^ binding
  *RAF1*     164760      CMD1NN                                              615916           AD            Promotes cardiomyocyte survival
  *DSP*      125647      CMD with woolly hair, keratoderma, tooth agenesis   615821, 605676   AD, AR        Obligate component of functional desmosomes
  *TCAP*     604488      CMD                                                 /                AD            Muscle assembly regulating factor that mediates antiparallel assembly of titin molecules at sarcomeric Z-disk
  *ANKRD1*   609599      CMD                                                 /                AD            Nuclear negative transcription factor that regulates expression of cardiac genes
  *TMPO*     188380      CMD                                                 /                AD            Regulates expression patterns of major cardiac transcription factors
  *ILK*      602366      CMD                                                 /                AD            Migration and survival of myocardial and endothelial cells
  *TNNI3*    191044      CMD2A, CMD1FF                                       611880, 613286   AR            Cardiac mediator of striated muscle relaxation
  *GATAD1*   614518      CMD2B                                               614672           AR            Regulates gene expression by binding to a histone modification site
  *FKTN*     607440      CMD1X                                               611615           AR            Glycosylation of alpha-dystroglycan in skeletal muscle
  *SDHA*     600857      CMD1GG                                              613642           AR            Major catalytic subunit of succinate-ubiquinone oxidoreductase located in mitochondrial respiratory chain
  *DMD*      300377      CMD3B                                               302045           XLR           Anchors extracellular matrix to cytoskeleton via F-actin
  *TAZ*      300394      CMD                                                 /                XLR           Involved in cardiolipin metabolism

CMD=dilated cardiomyopathy, LVNC=left ventricular non-compaction AD=autosomal dominant; AR=autosomal recessive XLR=X-linked recessive.

Ourmulti-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, MLPA to detect duplications and deletions in *LMNA, MYH7, SCN5A, BAG3, DES, EYA4, SGCD, MYBPC3, NEXN, PRDM16, PSEN1, TNNI3, DND, RAF1, FKTN* and *TAZ*.

Worldwide, 49 accredited medical genetic laboratories in the EU and 44 in the US, listed in the Orphanet ([@ref8]) and GTR ([@ref9]) databases, respectively, offer genetic testing for CMD. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref10]), GeneReviews ([@ref12]) and Clinical Utility Gene Card ([@ref16]).

Restrictive cardiomyopathy {#sec1-3}
==========================

Restrictive cardiomyopathy (RCM) is a rare genetic heart disease characterized by restrictive ventricle filling and diastolic dysfunction due to cardiac muscle stiffness which leads to abnormal relaxation of the ventricles, although thicknesses and systolic function are usually normal until later stages of the disease ([@ref17]). It can manifest at any time from childhood to adulthood. In children, the first signs may be failure to gain weight and thrive, fatigue and fainting. As the disease advances, there may be edema, ascites, hepatomegaly and lung congestion. Some children are totally asymptomatic and sudden death is the first manifestation. Adults with RCM first develop dyspnea, fatigue and reduced ability to exercise. Arrhythmia and palpitations are also typical of adults with RCM ([@ref18]). Restrictive cardiomyopathy is uncommon: in the US and Europe, it accounts for less than 5% of all cardiomyopathies. Prevalence is unknown ([@ref19]).

Clinical diagnosis is based on medical and family history, physical examination, chest X-ray, echocardiography, ECG, Holter monitoring, stress test, cardiac MRI, cardiac catheterization, coronary angiography and myocardial biopsy ([@ref18]). Genetic testing is useful for confirming diagnosis, and for differential diagnosis, recurrence risk evaluation and prenatal diagnosis in families with a known mutation. Differential diagnosis should consider constrictive pericarditis, idiopathic forms, such as Loeffler eosinophilic endomyocardial disease, secondary forms, such as infiltrative disease (amyloidosis, sarcoidosis, hemochromatosis, Fabry disease, Danon disease and Friedreich ataxia) and treatment-induced RCM (post-irradiation fibrosis and drug-induced RCM) ([@ref19]).

Restrictive cardiomyopathy typically has autosomal dominant inheritance ([Table 3](#T3){ref-type="table"}). Pathogenic variants may be missense, nonsense, splicing and small indels. Large deletions/duplications have been reported in *TNNI3, MYBPC3* and *MYH7*. MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and MLPA to detect duplications and deletions in the *TNNI3, MYBPC3* and *MYH7* genes. 6 accredited medical genetic laboratories in the US, listed in the GTR ([@ref9]) database, offer genetic tests for RCM. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref10]).

###### 

Genes associated with various forms of restrictive cardiomyopathy

  Gene       OMIM gene   Disease   OMIM disease   Inheritance   Function
  ---------- ----------- --------- -------------- ------------- --------------------------------------------------------------------------------------------------------------
  *TNNI3*    191044      RCM1      115210         AD            Cardiac mediator of striated muscle relaxation
  *TNNT2*    191045      RCM3      612422         AD            Ca^2+^-dependent regulator of muscle contraction
  *MYPN*     608517      RCM4      615248         AD            Component of the heart muscle sarcomere linking nebulette to alpha-actinin in Z lines
  *FLNC*     102565      RCM5      617047         AD            Critical for myogenesis and structural integrity of muscle fibers
  *ACTC1*    102540      RCM       /              AD            Localized in contractile apparatus of muscle tissue
  *MYH7*     160760      RCM       /              AD            Beta heavy chain subunit of cardiac myosin
  *MYBPC3*   600958      RCM       /              AD            Cardiac isoform of myosin-binding protein C found in cross-bridge-bearing zone (C region) of A bands
  *TPM1*     191010      RCM       /              AD            Ca^2+^-dependent regulator of striated muscle contraction
  *MYL1*     160780      RCM       /              AD            Regulatory light chain of myosin
  *MYL2*     160781      RCM       /              AD            Regulatory light chain associated with cardiac myosin beta heavy chain, promoting cardiac myofibril assembly

RCM=restrictive cardiomyopathy; AD=Autosomal dominant.

Left ventricular noncompaction {#sec1-4}
==============================

Left ventricular noncompaction (LVNC) is a heart disorder that affects the cardiac muscle, mostly the left ventricle, which acquires a thick spongy appearance. The disease is considered to be a consequence of an arrest in heart development during embryogenesis ([@ref20]). The abnormal cardiac muscle does not function properly, leading to progressive systolic and diastolic dysfunction. LVNC may be isolated or an element of other heart diseases.

The disorder has a variety of symptoms. Some patients may be entirely asymptomatic, while others fall victim to sudden death. Other symptoms or signs may be arrhythmia, palpitations, abnormal blood clots, fatigue, dyspnea and lymphedema ([@ref21]). Although the disease is genetic, age of onset is variable and diagnosis may be made from birth to late adulthood. The prevalence of LVNC is less than 0.25% ([@ref22]).

Clinical diagnosis is mainly based on structural features observed by cardiac imaging. Echocardiography is used for diagnosis and follow-up. MRI can be useful in cases with poor echocardiogram findings. Genetic testing is useful for confirming diagnosis and for differential diagnosis, recurrence risk evaluation and prenatal diagnosis in families with a known mutation. Differential diagnosis should consider dilated cardiomyopathy, hypertensive heart disease, apical hypertrophic cardiomyopathy, infiltrative cardiomyopathy, eosinophilic endomyocardial disease, localized left ventricular hypertrophy, left ventricular thrombi, cardiac metastases, endocardial fibroelastosis and Barth syndrome ([@ref23]).

Left ventricular noncompaction is a genetically heterogeneous disorder with sporadic and familial forms ([@ref24]). Autosomal dominant inheritance seems more common than X-linked inheritance ([@ref25]). Autosomal recessive inheritance and mitochondrial inheritance have also been observed ([@ref26]). Current evidence suggests that in most cases, an association with genetic cardiomyopathy (CMP) and/or congenital heart disease (CHD) is more likely than a causal role. Consequently, the genetic basis coincides or overlaps with those of CMP or CHD ([@ref27]). LVNC has mostly autosomal dominant inheritance, but may also have autosomal recessive inheritance ([Table 4](#T4){ref-type="table"}).

###### 

Genes associated with various forms of left ventricular noncompaction

  Gene        OMIM gene   Disease   OMIM disease   Inheritance   Function
  ----------- ----------- --------- -------------- ------------- ------------------------------------------------------------------------------------------------------
  *MYH7*      160760      LVNC5     613426         AD            Beta heavy chain subunit of cardiac myosin
  *MYBPC3*    600958      LVNC10    615396         AD            Cardiac isoform of myosin-binding protein C found in cross-bridge-bearing zone (C region) of A bands
  *TPM1*      191010      LVNC9     611878         AD            Ca^2+^-dependent regulation of striated muscle contraction
  *PRDM16*    605557      LVNC8     615373         AD            Transcriptional cofactor essential for heart development
  *MIB1*      608677      LVNC7     615092         AD            Involved in heart looping process
  *TNNT2*     191045      LVNC6     601494         AD            Ca^2+^-dependent regulator of muscle contraction
  *ACTC1*     102540      LVNC4     613424         AD            Localized in muscle tissue contractile system
  *LDB3*      605906      LVNC3     601493         AD            Adapter protein in striated muscle; couples protein kinase C-mediated signaling to cytoskeleton
  *DTNA*      601239      LVNC1     604169         AD            Component of dystrophin-associated protein complex; localized in sarcolemma
  *LMNA*      150330      LVNC      /              AD            Required for cardiac homeostasis
  *SCN5A*     600163      LVNC      /              AD            Mediates voltage-dependent Na^+^ permeability of excitable membranes
  *HCN4*      605206      LVNC      /              AD            Necessary for heart pacemaking
  *PLEKHM2*   609613      LVNC      /              AR            Regulates conventional kinesin activity
  *PKP2*      602861      LVNC      /              AR            Plays a role in junctional plaques
  *SOX6*      607257      LVNC      /              AR            Transcriptional activator required for maintenance of cardiac muscle cells
  *MT-ND1*    516000      LVNC      /              MT            Core subunit of mitochondrial membrane respiratory chain NADH dehydrogenase

LVNC=left ventricular noncompaction; AD=Autosomal dominant; AR=Autosomal recessive; MT=Mitochondrial.

Pathogenic variants may be sequence variations (missense, nonsense, splicing, small insertions and deletions, small indels). Large deletions/duplications have also been reported in *MYBPC3, MYH7, PKP2* and *PRDM16*. MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and MLPA to detect duplications and deletions in the same genes.

Worldwide, 40 accredited medical genetic laboratories in the EU and 4 in the US, listed in the Orphanet ([@ref8]) and GTR ([@ref9]) databases, respectively, offer genetic testing for LVNC. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref10]).

Arrhythmogenic right ventricular cardiomyopathy {#sec1-5}
===============================================

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart disease characterized by replacement of right ventricular myocytes with fibrous and fatty tissue. This predisposes young persons and athletes to ventricular tachycardia and even sudden death. Symptoms are not frequent in the early stages, but there is nevertheless risk of sudden death during intense exercise. When symptoms occur, they often include palpitations and syncope. Shortness of breath, swelling of the legs or heart failure are typical of a later stage of the disease. Patients usually develop symptoms between the second and fifth decade. The mean age at diagnosis is 31 years ([@ref28]).

Prevalence of ARVC is estimated at 1:1000-1250 in the general population ([@ref29]), but in countries with intensive family screening this disease appears to be much more common ([@ref30]). Study of a population in which males and females were equally distributed revealed that males were 3.3-fold more likely to be associated with episodes of arrhythmia ([@ref31]). Expression of the disease is variable, while penetrance is incomplete and age-related ([@ref32]).

To establish diagnosis, an International Task Force proposed criteria for clinical diagnosis of ARVC/dysplasia that facilitated recognition and interpretation of its often nonspecific clinical features. Structural, histological, electrocardiographic, arrhythmic and familial features of the disease were incorporated into the criteria, divided into major and minor categories according to the specificity of their association with ARVC/dysplasia. This provided a standard on which to base clinical research and genetic studies ([@ref33]). Differential diagnosis should consider idiopathic right ventricular outflow-tract tachycardia, cardiac sarcoidosis and congenital heart disease leading to right ventricular volume overload ([@ref34]).

Arrhythmogenic right ventricular cardiomyopathy has mostly autosomal dominant inheritance and only rarely autosomal recessive or digenic inheritance ([@ref28]). Pathogenic variants in the genes listed in [Table 5](#T5){ref-type="table"} have autosomal dominant inheritance ([@ref35]). Pathogenic variants may be missense, nonsense, splicing, small indels and gross deletions or duplications. MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and MLPA to detect duplications and deletions in *DSP* and *PKP2*.

###### 

Genes associated with various forms of arrhythmogenic right ventricular cardiomyopathy

  Gene       OMIM gene   Disease   OMIM disease   Inheritance   Function
  ---------- ----------- --------- -------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  *TGFB3*    190230      ARVC1     107970         AD            Involved in embryogenesis, differentiation, wound healing
  *RYR2*     180902      ARVC2     600996         AD            Ca^2+^ channel that releases Ca^2+^ from sarcoplasmic reticulum into cytoplasm and triggers cardiac muscle contraction
  *TMEM43*   612048      ARVC5     604400         AD            Maintains nuclear envelope structure
  *DSP*      125647      ARVC8     607450         AD            Forms obligate component of functional desmosomes
  *PKP2*     602861      ARVC9     609040         AD            Plays role in junctional plaques
  *DSG2*     125671      ARVC10    610193         AD            Ca^2+^-binding transmembrane glycoprotein components of desmosomes between myocardial cells
  *JUP*      173325      ARVC12    611528         AD            Common constituent of desmosomes and intermediate junctions
  *CTNNA3*   607667      ARVC13    615616         AD            Involved in formation of cell-cell adhesion complexes in muscle cells
  *TTN*      188840      ARVC      /              AD            Important for striated muscle assembly and functioning; connects microfilaments and contributes to balance of forces between two halves of sarcomere
  *DES*      125660      ARVC      /              AD            Sarcomeric microtubule-anchoring protein that maintains sarcomere structure
  *LMNA*     150330      ARVC      /              AD            Required for cardiac homeostasis
  *DSC2*     125645      ARVC11    610476         AD, AR        Major components of desmosomes (cell-cell junctions found in mechanically-stressed cells)

ARVC=arrhythmogenic right ventricular cardiomyopathy; AD=Autosomal dominant; AR=Autosomal recessive.

Worldwide, 46 accredited medical genetic laboratories in the EU and 22 in the US, listed in the Orphanet ([@ref8]) and GTR ([@ref9]) databases, respectively, offer genetic testing for ARVC. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref10]) and Clinical Utility Gene Card ([@ref35]).

Conclusions {#sec1-6}
===========

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with cardiac disorders. When a suspect of cardiomyopathy is present, we perform the analysis of all the genes present in this short article.

In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).
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